JPWO2022035866A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022035866A5 JPWO2022035866A5 JP2023510318A JP2023510318A JPWO2022035866A5 JP WO2022035866 A5 JPWO2022035866 A5 JP WO2022035866A5 JP 2023510318 A JP2023510318 A JP 2023510318A JP 2023510318 A JP2023510318 A JP 2023510318A JP WO2022035866 A5 JPWO2022035866 A5 JP WO2022035866A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- antigen
- cleavable linker
- polypeptide
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025078945A JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064268P | 2020-08-11 | 2020-08-11 | |
| US63/064,268 | 2020-08-11 | ||
| PCT/US2021/045395 WO2022035866A1 (en) | 2020-08-11 | 2021-08-10 | Cleavable linker compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078945A Division JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023547978A JP2023547978A (ja) | 2023-11-15 |
| JP2023547978A5 JP2023547978A5 (https=) | 2024-08-07 |
| JPWO2022035866A5 true JPWO2022035866A5 (https=) | 2024-08-07 |
| JP7681681B2 JP7681681B2 (ja) | 2025-05-22 |
Family
ID=80223911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023510318A Active JP7681681B2 (ja) | 2020-08-11 | 2021-08-10 | 切断可能リンカー組成物および方法 |
| JP2025078945A Pending JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025078945A Pending JP2025131591A (ja) | 2020-08-11 | 2025-05-09 | 切断可能リンカー組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11512113B2 (https=) |
| EP (2) | EP4196488B1 (https=) |
| JP (2) | JP7681681B2 (https=) |
| KR (2) | KR102944047B1 (https=) |
| CN (1) | CN116348597A (https=) |
| AU (1) | AU2026200907A1 (https=) |
| CA (1) | CA3187754A1 (https=) |
| ES (1) | ES3040950T3 (https=) |
| MX (1) | MX2023001788A (https=) |
| WO (1) | WO2022035866A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3287794A1 (en) * | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| US12534734B2 (en) * | 2018-05-15 | 2026-01-27 | Drive Therapeutics Llc | Stem-loop compositions and methods for inhibiting interleukin-8 |
| JP2024518539A (ja) | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| WO2022035866A1 (en) | 2020-08-11 | 2022-02-17 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2023161853A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| EP4615879A2 (en) * | 2022-11-11 | 2025-09-17 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
| WO2024150175A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| TW202540188A (zh) | 2023-12-01 | 2025-10-16 | 比利時商艾伯霖克斯公司 | 精準活化的多肽 |
| WO2025201560A1 (en) * | 2024-03-29 | 2025-10-02 | Vibrant Pharma Limited | Multispecific antigen-binding proteins and uses thereof |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US20010031264A1 (en) | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| BRPI0713421A2 (pt) | 2006-06-14 | 2012-03-13 | Imclone Systems Incorporated | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| CN104540518A (zh) | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| CN104271602B (zh) | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| IL270562B (en) | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| MX2017006016A (es) | 2014-11-11 | 2017-06-19 | Amunix Operating Inc | Composiciones conjugadas de xten direccionadas y metodos para producir las mismas. |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| MX2019004775A (es) | 2016-11-03 | 2019-08-05 | Squibb Bristol Myers Co | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos. |
| CA3287794A1 (en) | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| CN120463822A (zh) | 2018-09-27 | 2025-08-12 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| MY205459A (en) | 2018-12-06 | 2024-10-22 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CN114423499A (zh) | 2019-06-06 | 2022-04-29 | 佳努克斯治疗公司 | 与肿瘤激活的t细胞衔接子相关的组合物和方法 |
| US20230121775A1 (en) | 2019-06-26 | 2023-04-20 | Amunix Pharmaceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| WO2022035866A1 (en) * | 2020-08-11 | 2022-02-17 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
-
2021
- 2021-08-10 WO PCT/US2021/045395 patent/WO2022035866A1/en not_active Ceased
- 2021-08-10 EP EP21856576.0A patent/EP4196488B1/en active Active
- 2021-08-10 CN CN202180069665.6A patent/CN116348597A/zh active Pending
- 2021-08-10 CA CA3187754A patent/CA3187754A1/en active Pending
- 2021-08-10 ES ES21856576T patent/ES3040950T3/es active Active
- 2021-08-10 KR KR1020237008265A patent/KR102944047B1/ko active Active
- 2021-08-10 US US17/398,500 patent/US11512113B2/en active Active
- 2021-08-10 EP EP25185336.2A patent/EP4631977A3/en active Pending
- 2021-08-10 JP JP2023510318A patent/JP7681681B2/ja active Active
- 2021-08-10 KR KR1020267008789A patent/KR20260042619A/ko active Pending
- 2021-08-10 MX MX2023001788A patent/MX2023001788A/es unknown
-
2022
- 2022-10-24 US US17/972,348 patent/US20230147782A1/en not_active Abandoned
-
2024
- 2024-09-19 US US18/890,543 patent/US20250019403A1/en not_active Abandoned
-
2025
- 2025-05-09 JP JP2025078945A patent/JP2025131591A/ja active Pending
-
2026
- 2026-02-09 AU AU2026200907A patent/AU2026200907A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022035866A5 (https=) | ||
| JP2022046569A5 (https=) | ||
| JPWO2020118109A5 (https=) | ||
| JP2019513014A5 (https=) | ||
| JP2022065174A5 (https=) | ||
| US8846861B2 (en) | Peptide clearing agents | |
| JP2026004397A5 (https=) | ||
| JP2018504925A5 (https=) | ||
| US20130266568A1 (en) | Activatable bispecific antibodies | |
| IL261432B1 (en) | Induced binding proteins and methods of use | |
| US20100189727A1 (en) | Masking Ligands For Reversible Inhibition Of Multivalent Compounds | |
| JP2012511033A5 (https=) | ||
| AU2021208553A1 (en) | Cytokine IL-2 prodrugs comprising a cleavable linker | |
| US20240400696A1 (en) | Compositions targeting epidermal growth factor receptor and methods for making and using the same | |
| JPWO2021236676A5 (https=) | ||
| JPWO2022125576A5 (https=) | ||
| JPWO2022125566A5 (https=) | ||
| JPWO2022040128A5 (https=) | ||
| JPWO2022240637A5 (https=) | ||
| JPWO2023068377A5 (https=) | ||
| US20190270828A1 (en) | Tandem antibodies | |
| Breurken et al. | Semi-synthesis of a protease-activatable collagen targeting probe | |
| WO2024131774A9 (zh) | 新型冠状病毒奥密克戎突变株广谱中和抗体及应用 | |
| WO2024131775A9 (zh) | 新型冠状病毒xbb.1.5及相关变异株广谱中和抗体及应用 | |
| NZ772087B2 (en) | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |